A new selective vascular endothelial growth factor receptor 2 inhibitor ablates disease in a mouse model of psoriasis

Yan,Heng-Xiu; Wang,Yong; Yang,Xiao-Nong; Fu,Li-Xin; Tang,Dong-Mei

doi:10.3892/mmr.2013.1500

A new selective vascular endothelial growth factor receptor 2 inhibitor ablates disease in a mouse model of psoriasis

Authors:
- Heng-Xiu Yan
- Yong Wang
- Xiao-Nong Yang
- Li-Xin Fu
- Dong-Mei Tang
View Affiliations

Affiliations: College of Life Science and Technology, Southwest University for Nationalities, Chengdu, Sichuan, P.R. China
Published online on: May 31, 2013 https://doi.org/10.3892/mmr.2013.1500
Pages: 434-438

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Psoriasis is a common chronic inflammatory skin disease and its underlying pathogenesis is still not fully understood. Therapeutic interventions are currently limited and restricted to the treatment of symptoms rather than targeting the mechanisms underlying the disease. Vascular remodeling is a hallmark of psoriasis; however, anti-vascular strategies to treat psoriasis have received little attention to date, particularly systemic treatment with a small molecule compound. The aim of this study was to investigate the anti-inflammatory effect of a newly identified vascular endothelial growth factor (VEGF) receptor 2 inhibitor, SKLB1002, and its possible mechanism of action in a transgenic mouse model of psoriasis. Fifteen 8-12-week‑old K14-VEGF transgenic mice received consecutive intraperitoneal (i.p.) injections of SKLB1002, vehicle or saline for 4 weeks. After 4 weeks of treatment, the disease symptoms were assessed and histological analyses were performed on ear sections by hematoxylin and eosin (HE) and immunohistochemistry staining. Systemic treatment with SKLB1002 reduced symptoms of ear inflammation in K14/VEGF transgenic mice, the pathological score was significantly decreased, and acanthosis, focal parakeratosis, hyperkeratosis and hemangiectasis were improved. Furthermore, systemic treatment with SKLB1002 significantly reduced vascular abnormalities, permeability and T-cell infiltration. These results demonstrated that targeted inhibition of VEGFR2 by a small molecule inhibitor is an effective method, which may be a new therapeutic option for psoriasis therapy.

View Figures

View References

1	Christensen TE, Callis KP, Papenfuss J, et al: Observations of psoriasis in the absence of therapeutic intervention identifies two unappreciated morphologic variants, thin-plaque and thick-plaque psoriasis, and their associated phenotypes. J Invest Dermatol. 126:2397–2403. 2006. View Article : Google Scholar
2	Bowcock AM and Krueger JG: Getting under the skin: the immunogenetics of psoriasis. Nat Rev Immunol. 5:699–711. 2005. View Article : Google Scholar : PubMed/NCBI
3	Creamer D, Allen MH, Sousa A, Poston R and Barker JN: Localization of endothelial proliferation and microvascular expansion in active plaque psoriasis. Br J Dermatol. 136:859–865. 1997. View Article : Google Scholar : PubMed/NCBI
4	Pinkus H and Mehregan AH: The primary histologic lesion of seborrheic dermatitis and psoriasis. J Invest Dermatol. 46:109–116. 1966.PubMed/NCBI
5	Liew SC, Das-Gupta E, Chakravarthi S, et al: Differential expression of the angiogenesis growth factors in psoriasis vulgaris. BMC Res Notes. 5:2012012. View Article : Google Scholar : PubMed/NCBI
6	Detmar M, Brown LF, Claffey KP, et al: Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med. 180:1141–1146. 1994. View Article : Google Scholar : PubMed/NCBI
7	Flisiak I, Zaniewski P, Rogalska M, Mysliwiec H, Jaroszewicz J and Chodynicka B: Effect of psoriasis activity on VEGF and its soluble receptors concentrations in serum and plaque scales. Cytokine. 52:225–229. 2010. View Article : Google Scholar : PubMed/NCBI
8	Cordiali-Fei P, Trento E, D’Agosto G, et al: Effective therapy with anti-TNF-alpha in patients with psoriatic arthritis is associated with decreased levels of metalloproteinases and angiogenic cytokines in the sera and skin lesions. Ann NY Acad Sci. 1110:578–589. 2007. View Article : Google Scholar : PubMed/NCBI
9	Nielsen HJ, Christensen IJ, Svendsen MN, et al: Elevated plasma levels of vascular endothelial growth factor and plasminogen activator inhibitor-1 decrease during improvement of psoriasis. Inflamm Res. 51:563–567. 2002. View Article : Google Scholar
10	Detmar M: The role of VEGF and thrombospondins in skin angiogenesis. J Dermatol Sci. 24(Suppl 1): S78–S84. 2000. View Article : Google Scholar : PubMed/NCBI
11	Yano K, Kajiya K, Ishiwata M, Hong YK, Miyakawa T and Detmar M: Ultraviolet B-induced skin angiogenesis is associated with a switch in the balance of vascular endothelial growth factor and thrombospondin-1 expression. J Invest Dermatol. 122:201–208. 2004. View Article : Google Scholar : PubMed/NCBI
12	Man XY, Yang XH, Cai SQ, Yao YG and Zheng M: Immunolocalization and expression of vascular endothelial growth factor receptors (VEGFRs) and neuropilins (NRPs) on keratinocytes in human epidermis. Mol Med. 12:127–136. 2006.PubMed/NCBI
13	Elias PM, Arbiser J, Brown BE, et al: Epidermal vascular endothelial growth factor production is required for permeability barrier homeostasis, dermal angiogenesis, and the development of epidermal hyperplasia: implications for the pathogenesis of psoriasis. Am J Pathol. 173:689–699. 2008. View Article : Google Scholar
14	Canavese M, Altruda F, Ruzicka T and Schauber J: Vascular endothelial growth factor (VEGF) in the pathogenesis of psoriasis - a possible target for novel therapies? J Dermatol Sci. 58:171–176. 2010. View Article : Google Scholar : PubMed/NCBI
15	Cao Y: Opinion: emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis. Nat Rev Cancer. 5:735–743. 2005. View Article : Google Scholar : PubMed/NCBI
16	Zhang S, Cao Z, Tian H, et al: SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo. Clin Cancer Res. 17:4439–4450. 2011. View Article : Google Scholar : PubMed/NCBI
17	Hedlund EM, Yang X, Zhang Y, et al: Tumor cell-derived placental growth factor sensitizes antiangiogenic and antitumor effects of anti-VEGF drugs. Proc Natl Acad Sci. 110:654–659. 2013. View Article : Google Scholar : PubMed/NCBI
18	Xia YP, Li B, Hylton D, Detmar M, Yancopoulos GD and Rudge JS: Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood. 102:161–168. 2003. View Article : Google Scholar : PubMed/NCBI
19	Baker BS, Brent L, Valdimarsson H, et al: Is epidermal cell proliferation in psoriatic skin grafts on nude mice driven by T-cell derived cytokines? Br J Dermatol. 126:105–110. 1992. View Article : Google Scholar : PubMed/NCBI
20	Lowes MA, Chamian F, Abello MV, et al: Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci USA. 102:19057–19062. 2005. View Article : Google Scholar : PubMed/NCBI
21	Schonthaler HB, Huggenberger R, Wculek SK, Detmar M and Wagner EF: Systemic anti-VEGF treatment strongly reduces skin inflammation in a mouse model of psoriasis. Proc Natl Acad Sci USA. 106:21264–21269. 2009. View Article : Google Scholar : PubMed/NCBI
22	Ferrara N, Gerber HP and LeCouter J: The biology of VEGF and its receptors. Nat Med. 9:669–676. 2003. View Article : Google Scholar : PubMed/NCBI
23	Kunstfeld R, Hirakawa S, Hong YK, et al: Induction of cutaneous delayed-type hypersensitivity reactions in VEGF-A transgenic mice results in chronic skin inflammation associated with persistent lymphatic hyperplasia. Blood. 104:1048–1057. 2004. View Article : Google Scholar : PubMed/NCBI
24	Dvorak HF, Brown LF, Detmar M and Dvorak AM: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 146:1029–1039. 1995.PubMed/NCBI
25	Detmar M, Brown LF, Schon MP, et al: Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J Invest Dermatol. 111:1–6. 1998. View Article : Google Scholar : PubMed/NCBI